A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 11, 2024

Conditions

End Stage Renal DiseaseRenal Impairment

Interventions

DRUG

Belzutifan

Three 40 mg tablets given as a single oral 120 mg dose.

Trial Locations (1)

Orlando Clinical Research Center ( Site 0001), Orlando

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY